Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

Madeleine M. Hipp, Norbert Hilf, Steffen Walter, Daniela Werth, Katharina M. Brauer, Markus P. Radsak, Toni Weinschenk, Harpreet Singh-Jasuja, Peter Brossart

Blood (2008) 111 (12): 5610–5620.

https://doi.org/10.1182/blood-2007-02-075945

Published: 2008

Includes: Supplemental data

Journal Articles

Imatinib Inhibits Proteasomal Activity in CML Cells.

Stefanie A.E. Held, Katharina M. Brauer, Thomas Rückrich, Daniela Werth, Karin von Schwarzenberg, Anita Bringmann, Lothar Kanz, Frank Grünebach, Christoph Driessen, Peter Brossart

Blood (2007) 110 (11): 4531.

https://doi.org/10.1182/blood.V110.11.4531.4531

Published: 2007

Journal Articles

Zoledronic Acid Inhibits the Function of Toll-Like Receptor 4 Ligand Activated Dendritic Cells.

Anita Bringmann, Susanne M. Schmidt, Katharina M. Brauer, Karin von Schwarzenberg, Daniela Werth, PhD, Lothar Kanz, MD, Peter Brossart, MD

Blood (2006) 108 (11): 3843.

https://doi.org/10.1182/blood.V108.11.3843.3843

Published: 2006

Journal Articles

Identification and Characterization of T Cell Epitopes Deduced from RGS5, a Novel Broadly Expressed Tumor Antigen.

Cristina N. Boß, Frank Grünebach, PhD, Katharina M. Brauer, Toni Weinschenk, PhD, Lothar Kanz, MD, Stefan Stevanovic, PhD, Hans-Georg Rammensee, PhD, Peter Brossart, MD

Blood (2006) 108 (11): 3703.

https://doi.org/10.1182/blood.V108.11.3703.3703

Published: 2006

Journal Articles

Interleukin-10 Severely Impairs TLR Mediated Activation of Antigen Presenting Cells.

Anja Knödler, Anita Bringmann, Markus M. Weck, PhD, Katharina M. Brauer, Lothar Kanz, MD, Frank Grünebach, PhD, Peter Brossart, MD

Blood (2006) 108 (11): 929.

https://doi.org/10.1182/blood.V108.11.929.929

Published: 2006

Journal Articles

BCR-ABL Activity Is Critical for the Immunogenicity of Chronic Myelogenous Leukemia Cells.

Katharina M. Brauer, Daniela Werth, PhD, Karin von Schwarzenberg, Anita Bringmann, Lothar Kanz, MD, Frank Grünebach, PhD, Peter Brossart, MD

Blood (2006) 108 (11): 2202.

https://doi.org/10.1182/blood.V108.11.2202.2202

Published: 2006

Journal Articles

Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation

Alessio Nencioni, Karin Schwarzenberg, Katharina M. Brauer, Susanne M. Schmidt, Alberto Ballestrero, Frank Grünebach, Peter Brossart

Blood (2006) 108 (2): 551–558.

https://doi.org/10.1182/blood-2005-08-3494

Published: 2006

NARROW

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

Imatinib Inhibits Proteasomal Activity in CML Cells.

Zoledronic Acid Inhibits the Function of Toll-Like Receptor 4 Ligand Activated Dendritic Cells.

Identification and Characterization of T Cell Epitopes Deduced from RGS5, a Novel Broadly Expressed Tumor Antigen.

Interleukin-10 Severely Impairs TLR Mediated Activation of Antigen Presenting Cells.

BCR-ABL Activity Is Critical for the Immunogenicity of Chronic Myelogenous Leukemia Cells.

Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation

Email alerts

ASH Publications

American Society of Hematology

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

Imatinib Inhibits Proteasomal Activity in CML Cells.

Zoledronic Acid Inhibits the Function of Toll-Like Receptor 4 Ligand Activated Dendritic Cells.

Identification and Characterization of T Cell Epitopes Deduced from RGS5, a Novel Broadly Expressed Tumor Antigen.

Interleukin-10 Severely Impairs TLR Mediated Activation of Antigen Presenting Cells.

BCR-ABL Activity Is Critical for the Immunogenicity of Chronic Myelogenous Leukemia Cells.

Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only